Compare MGNI & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNI | AVDL |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Ireland |
| Employees | 905 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | MGNI | AVDL |
|---|---|---|
| Price | $14.77 | $21.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $26.80 | $18.38 |
| AVG Volume (30 Days) | ★ 3.4M | 2.7M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 219.02 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $702,565,000.00 | $248,517,000.00 |
| Revenue This Year | $2.09 | $64.21 |
| Revenue Next Year | $11.41 | $30.80 |
| P/E Ratio | $38.71 | ★ N/A |
| Revenue Growth | 6.27 | ★ 79.88 |
| 52 Week Low | $8.22 | $6.38 |
| 52 Week High | $26.65 | $23.57 |
| Indicator | MGNI | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 61.13 |
| Support Level | $13.08 | $21.18 |
| Resistance Level | $15.14 | $23.18 |
| Average True Range (ATR) | 0.70 | 0.42 |
| MACD | 0.26 | -0.11 |
| Stochastic Oscillator | 69.76 | 57.44 |
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.